+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
IPCALAB

Ipca Laboratories Share Price

₹1,962.60 -29.8 (-1.5%)
New 52W High in past week

23 Sep, 2026 3:58 PM (IST)

Ipca Laboratories live price: ₹1,962.60. It opened at ₹1,993 vs previous close ₹1,992; intraday high/low: ₹1,999/₹1,949. The 50 & 200 DMA stand at ₹1,877.00/₹1,663.90.

Ipca Laboratories Performance

  • Today's Low
  • ₹1,949
  • Today's High
  • ₹1,999
  • 52 Week Low
  • ₹1,252
  • 52 Week High
  • ₹2,038
  • Open Price₹1,993
  • Previous Close₹1,992
  • Volume164,527
  • 50 DMA₹1,877.00
  • 100 DMA₹1,778.90
  • 200 DMA₹1,663.90

Ipca Laboratories Chart

Investment Returns

  • Over 1 Month + 2.69%
  • Over 3 Month + 22.87%
  • Over 6 Month + 27.04%
  • Over 1 Year + 40.26%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 38
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 49,792
  • P/B Ratio
  • 5.9
  • Average True Range
  • 54.5
  • EPS
  • 51.6
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 33.3
  • RSI
  • 55.52
  • MFI
  • 60.22

Latest Stock News Updates

Ipca Laboratories Ltd - 524494 - Closure of Trading Window

Closure of Trading Window

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Transcript of Conference Call

Ipca surges 11% in tepid market, nears 52-week high on healthy Q1 results

Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,962.60
-29.8 (-1.5%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹1,953.30
  • 50 Day
  • ₹1,877.00
  • 100 Day
  • ₹1,778.90
  • 200 Day
  • ₹1,663.90

Resistance and Support

1970.17 Pivot Speed
  • R3 2,042.70
  • R2 2,021.10
  • R1 1,991.80
  • S1 1,940.90
  • S2 1,919.30
  • S3 1,890.00

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-13 Quarterly Results
2026-05-29 Audited Results & Dividend
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
Date Purpose Remarks
2026-08-07 FINAL Rs.6.00 per share(600%)Dividend
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Stock split from Rs. 2/- to Re. 1/-.
2010-03-23 Split

Ipca Laboratories Shareholding Pattern

44.72%
31.15%
10.72%
7.19%
6.21%

About Ipca Laboratories

Ipca Laboratories is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical ingredients (APIs).(Source : AR-PDF:202603-01 Pg No: 114) View More
  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Executive Director.(Professional.),Managing Director,Chief Financial Officer,Non Promoter
  • A K Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,962 As on 24 September, 2026 | 06:30

The Market Cap of Ipca Laboratories is ₹49792 Cr As on 24 September, 2026 | 06:30

The P/E ratio of Ipca Laboratories is 38 As on 24 September, 2026 | 06:30

The PB ratio of Ipca Laboratories is 5.9 As on 24 September, 2026 | 06:30

The 52 week High & Low of Ipca Laboratories is ₹2038/₹1251.6 respectively As on 24 September, 2026 | 06:30

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23